Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Trifluridine/Tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04097028 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT04097028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04097028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Trifluridine/Tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2019
Completion date
February 5, 2025
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iia esophageal adenocarcinoma ajcc v8, clinical stage iia gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva esophageal adenocarcinoma ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iib esophageal adenocarcinoma ajcc v8, pathologic stage iib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iii esophageal adenocarcinoma ajcc v8, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia esophageal adenocarcinoma ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib esophageal adenocarcinoma ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva esophageal adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8